CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Apollo ESG with ERBE HAPC +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05559866
NCT05559866N/ACompleted
CompareCT.gov

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial (HAPCET): A Single-center Randomized Controlled Trial

Mayo Clinic·interventional·Posted Sep 29, 2022·Updated Oct 23, 2025

In Brief

A clinical study evaluating Apollo ESG with ERBE HAPC and Apollo ESG for Obesity. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This study is being done to evaluate the safety and effectiveness of combined Hybrid Argon Plasma Coagulation (HAPC) and Endoscopic Sleeve Gastroplasty (ESG) for weight loss and improvement in obesity-related co-morbidities compared to ESG alone in participants with a BMI ≥ 30 and ≤40 kg/m² who have failed to achieve and maintain weight loss with a non-surgical program.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsErbe Elektromedizin GmbH

Timeline

N/ACompletedFinished
2023202420252026
First PostedSep 29, 2022
Enrollment StartNov 18, 2022
Primary CompletionAug 2, 2024
Study CompletionJan 17, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.8 years ago

Interventions

Apollo ESG with ERBE HAPCdevice

Utilizing two approved devices in combination to assess durability of suturing.

Apollo ESGdevice

Using only Apollo ESG as approved per label.